About: Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses
Creator	Hoekstra, Gabriel Horvath, Katie Stone, Michelle Tian, Shaomin Yi, Xianwen De Silva, Aravinda Luft, Chris Metz, Stefan Miley, Michael Desimone, Joseph
Source	PMC
abstract	Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year. Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology. Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
has issue date	2016-10-20(xsd:dateTime)
bibo:doi	10.1371/journal.pntd.0005071
bibo:pmid	27764114
has license	cc-by
sha1sum (hex)	cbabbd687725e949c99a0a6f53f033128ea1aaca
schema:url	https://doi.org/10.1371/journal.pntd.0005071
resource representing a document's title	Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses
has PubMed Central identifier	PMC5072622
has PubMed identifier	27764114
schema:publication	PLoS Negl Trop Dis
resource representing a document's body	covid:cbabbd687725e949c99a0a6f53f033128ea1aaca#body_text
is schema:about of	named entity 'RESPONSES' named entity 'PRINT' named entity 'dengue' named entity 'Proteins' named entity 'Antibody' named entity 'NEUTRALIZING ANTIBODY' named entity 'DENV-E' named entity 'COUNTRIES' named entity 'INFECTIONS' named entity 'DENGUE HEMORRHAGIC FEVER' named entity 'DENGUE' named entity 'USING' named entity 'SPECIFIC IMMUNITY' named entity 'INDUCE' named entity 'DISEASE' named entity 'PROTECTION' named entity 'BASED' named entity 'ENHANCE' named entity 'CAUSING' named entity 'VIRUS' named entity 'NON-' named entity 'TEMPLATE' named entity 'WETTING' named entity 'DENGUE FEVER' named entity 'PER YEAR' named entity 'PARTIAL' named entity 'EVIDENCE' named entity 'SIMULTANEOUS' named entity 'NEED' named entity 'MILLION' named entity '120' named entity 'BALANCED' named entity 'ENDEMIC' named entity 'SEROTYPES' named entity 'LIVE' named entity 'VACCINATION' named entity 'NANOPARTICLES' named entity 'PROTEINS' named entity 'VACCINES' named entity 'REPLICATION' named entity 'EXPLORING' named entity 'NANOPARTICLE' named entity 'ROBUST' named entity 'DISPLAYING' named entity 'SEROTYPE' named entity 'DISPLAY' named entity 'ATTENUATED' named entity 'SUBUNIT VACCINE' named entity 'HAVE' named entity 'EFFICACY' named entity 'PARTICULATE' named entity 'DENGUE VIRUS' named entity 'VACCINE DEVELOPMENT' named entity '4 SEROTYPES' named entity 'SPECIFIC' named entity 'PARTICLE' named entity 'PROTECTIVE IMMUNITY' named entity 'PROTEIN ' named entity 'DUE TO' named entity 'TECHNOLOGY' named entity 'CAUSATIVE AGENT' named entity '350' named entity 'CONDITIONS' named entity 'POTENTIALS' named entity 'DISTINCT' covid:arg/cbabbd687725e949c99a0a6f53f033128ea1aaca named entity 'balanced' named entity 'precisely' named entity 'efficacy' named entity 'While' named entity 'Dengue virus' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software